SynthesisFrontiers in microbiology2025
Hypertension-gut microbiota research trends: a bibliometric and visualization analysis (2000-2025).
Synthesis in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Hypertension and frailty in older adults: a bibliometric analysis and knowledge mapping based on Web of Science, Scopus, and PubMed (1973-2025).Frontiers in medicine · 2026Pooled it
- Gut microbiota dysbiosis and systemic inflammation in elderly Chinese hypertensive patients: a case-control study.Frontiers in immunology · 2025Article
- Cross-sectional study on ethnic variations in gut microbiome diversity and hypertension severity.Bioinformation · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hypertension is a major global public health challenge affecting over 1.3 billion people. Emerging evidence indicates that gut microbiota regulates blood pressure through metabolic and immune-inflammatory pathways. This provides novel insights into hypertension mechanisms and facilitates targeted interventions. However, research in this field faces three major challenges: (1) fragmented knowledge, (2) limited clinical translation, and (3) unclear developmental trajectories. Consequently, conventional reviews cannot adequately capture its dynamic evolution. Objective: Using publications from the Web of Science Core Collection (2000-2025), we conducted a bibliometric analysis with CiteSpace and VOSviewer to map collaborative networks, analyze research hotspot evolution, identify emerging frontiers, and provide quantitative insights for field advancement. Methods: We retrieved 2,827 qualified publications through Boolean logic search, then performed analyses including: annual publication trends, national/institutional/author collaboration networks, keyword co-occurrence and clustering, burst detection, and timeline/mountain range visualizations using CiteSpace and VOSviewer. Results: Publication trends evolved through three phases: initial accumulation (annual output <50), accelerated growth, and stable maturation (250-450 annually). Driven by technology and clinical needs, China (918) and the US (676) led research, with networks involving Italy, Spain, etc. Academic institutions like the Univ. of Florida and Zhejiang Univ. were pivotal, and key teams (e.g., Yang Tao, Raizada Mohan K.) focused on mechanisms and translation. Research hotspots centered on "gut microbiota" and "blood pressure," forming three modules: metabolic regulation, complication associations, and intervention strategies. Cluster analysis identified 10 groups-including short-chain fatty acids and TMAO-spanning basic to clinical research. Post-2017 foci like Conclusion: This study establishes a quantitative analytical framework for hypertension-gut microbiota research, revealing a collaborative landscape led by China and the United States with multidisciplinary integration. We identify metabolic reprogramming and microbiota-targeted interventions as core research priorities, providing theoretical foundations to address clinical translation barriers and advance precision medicine. Future research should strengthen cross-disciplinary collaboration, prioritize investigation of ethnicity-specific microbial signatures and microbiota-drug interactions, and accelerate clinical translation of targeted therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.